NCT05245500 2025-12-05Phase 1 Study of MRTX1719 in Solid Tumors With MTAP DeletionBristol-Myers SquibbPhase 1 Recruiting336 enrolled
NCT06603987 2025-11-19Using CICS-1 and SPM-011 and ï¼»18Fï¼½FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMAStella Pharma CorporationPhase 1/2 Enrolling by invitation30 enrolled
NCT05732831 2025-11-14Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid TumorsTango Therapeutics, Inc.Phase 1/2 Recruiting225 enrolled
NCT06638931 2025-05-28ANTARESInstituto do Cancer do Estado de São PauloPhase 2 Active not recruiting28 enrolled
NCT00154388 2016-11-18Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare DiseasesNovartisPhase 2 Completed185 enrolled